Transistor (https://transistor.fm) https://feeds.transistor.fm/paradigm-pulse Listen to audio from accredited CME activities from Paradigm Medical Communications, featuring expert faculty discussions and the latest clinical insights. Visit the link in each episode description to access the full activity and claim CME credit. © 2026 Paradigm Medical Communications, LLC. 29dd7fcc-7835-5a7d-b314-339ca807395c yes en Mon, 03 Aug 2026 11:18:20 -0700 Mon, 03 Aug 2026 11:19:21 -0700 https://img.transistorcdn.com/8HtDSbsDfFKLpknaB6-hqq4n8PaYiOrLoxldQslDMOM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYmRi/ZmZmYTBlN2UwZDVj/MzFjZmZjZTdlMWFm/YmMzNi5wbmc.jpg episodic Paradigm Medical Communications, LLC. Listen to audio from accredited CME activities from Paradigm Medical Communications, featuring expert faculty discussions and the latest clinical insights. Visit the link in each episode description to access the full activity and claim CME credit. Listen to audio from accredited CME activities from Paradigm Medical Communications, featuring expert faculty discussions and the latest clinical insights. CME, Continuing Medical Education, Medical Education, Clinical Updates, Evidence-Based Medicine, Healthcare Professionals, Physician Education, Medical Podcast, Continuing Education, Expert Insights Paradigm Medical Communications, LLC medicaleducation@paradigmmc.org No No 1 1 New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus full ecf954ca-79ec-4488-b0c7-644c220df01e https://share.transistor.fm/s/45ae9d98 Please CLICK HERE (https://activities.paradigmmc.com/1460P) to view the full CME activity and claim credit for your participation.

• (00:00) - Welcome and Introduction
• (05:54) - B Cell Targets in Lupus
• (07:58) - Targeting BAFF
• (11:55) - Dual Targeting APRIL and BAFF
• (15:11) - B-Cell Depletion Via the BAFF Receptor
• (17:57) - Type II Anti-CD20
• (28:20) - Bispecific T-Cell Engagers
• (32:51) - CAR-T Cells in SLE

B cells play a major role in the pathology of systemic lupus erythematosus (SLE), and several treatments have focused on blocking activation or depleting large subsets of B cells based on surface markers. From anti-CD20 antibodies to chimeric antigen receptor (CAR) T cells, varying depths of B-cell depletion have demonstrated a range of efficacies and durations of response. In addition, these treatments vary in administration, preparation, ease of use, and potential adverse effects. The faculty will provide an engaging discussion on the categories of emerging B-cell therapies and their potential use in SLE.]]> Please CLICK HERE (https://activities.paradigmmc.com/1460P) to view the full CME activity and claim credit for your participation.

• (00:00) - Welcome and Introduction
• (05:54) - B Cell Targets in Lupus
• (07:58) - Targeting BAFF
• (11:55) - Dual Targeting APRIL and BAFF
• (15:11) - B-Cell Depletion Via the BAFF Receptor
• (17:57) - Type II Anti-CD20
• (28:20) - Bispecific T-Cell Engagers
• (32:51) - CAR-T Cells in SLE

B cells play a major role in the pathology of systemic lupus erythematosus (SLE), and several treatments have focused on blocking activation or depleting large subsets of B cells based on surface markers. From anti-CD20 antibodies to chimeric antigen receptor (CAR) T cells, varying depths of B-cell depletion have demonstrated a range of efficacies and durations of response. In addition, these treatments vary in administration, preparation, ease of use, and potential adverse effects. The faculty will provide an engaging discussion on the categories of emerging B-cell therapies and their potential use in SLE.]]> Mon, 03 Aug 2026 11:02:35 -0700 Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC. 2343 Please CLICK HERE (https://activities.paradigmmc.com/1460P) to view the full CME activity and claim credit for your participation.

• (00:00) - Welcome and Introduction
• (05:54) - B Cell Targets in Lupus
• (07:58) - Targeting BAFF
• (11:55) - Dual Targeting APRIL and BAFF
• (15:11) - B-Cell Depletion Via the BAFF Receptor
• (17:57) - Type II Anti-CD20
• (28:20) - Bispecific T-Cell Engagers
• (32:51) - CAR-T Cells in SLE

B cells play a major role in the pathology of systemic lupus erythematosus (SLE), and several treatments have focused on blocking activation or depleting large subsets of B cells based on surface markers. From anti-CD20 antibodies to chimeric antigen receptor (CAR) T cells, varying depths of B-cell depletion have demonstrated a range of efficacies and durations of response. In addition, these treatments vary in administration, preparation, ease of use, and potential adverse effects. The faculty will provide an engaging discussion on the categories of emerging B-cell therapies and their potential use in SLE.]]> CME, Continuing Medical Education, Medical Education, Clinical Updates, Evidence-Based Medicine, Healthcare Professionals, Physician Education, Medical Podcast, Continuing Education, Expert Insights No